alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 2,926–2,950 of 3,858 studies published 2025 (page 118 of 155) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Integrative and interpretable framework to unveil the neurophysiological fingerprint of Alzheimer’s disease and mild cognitive impairment: A machine learning-SHAP approach

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Applied Biomedicine 2025-06-13

Dementia and mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) are neurological pathologies associated with disruptions in brain electromagnetic activity, typically studied using magnetoencephalography (MEG) and electroencephalography (EEG). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mapping knowledge landscapes and emerging trends in digital biomarkers for dementia in older adults: A scoping and bibliometric analysis

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Archives of Gerontology and Geriatrics Plus 2025-04-09

This paper presents a systematic bibliometric analysis of the research landscape at the intersection of Alzheimer's disease and gerontechnology, identifying key contributors, research hotspots, and emerging trends. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identifying syntactic biomarkers of cognitive impairment in Mandarin-speaking older adults by applying machine learning approaches across multiple speech tasks

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Aphasiology 2025-05-28

The use of linguistic biomarkers for detecting cognitive decline and early stages of dementia has demonstrated great potential due to its low-cost and non-invasive nature, especially towards a large aging population. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Alzheimer's and dementia: Diagnosis, assessment, and disease monitoring global, regional, and national burden of Alzheimer's disease and other dementias (ADODs) and their risk factors, 1990–2021: A systematic analysis for the Global Burden of Disease study 2021

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2025-04-01

Between 1990 and 2021, ADOD incidence, prevalence, deaths, and DALYs increased significantly. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Early Detection of White Matter Integrity Changes in Down Syndrome: The Promise of PSMD as a Sensitive Biomarker

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-12-01

In DS, PSMD changed approximately 10‐15 years before the onset of AD symptoms and linearly increased with AD clinical stages, AD pathology, and SVD metrics. 4 key findings →

Participants: 70 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Molecular Neurodegeneration 2025-08-12

Lewy body dementia (LBD) is a neurodegenerative disorder characterized by a combination of progressive dementia and spontaneous parkinsonian symptoms. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Peripheral Single‐Cell Immune Characteristics Contribute to the Diagnosis of Alzheimer's Disease and Dementia With Lewy Bodies

✓ Peer-reviewed alzhub usefulness score 38 out of 100. CNS Neuroscience & Therapeutics 2025-01-01

These models demonstrated high diagnostic efficacy in distinguishing diseased samples from healthy donors as well as distinguishing AD and DLB cases. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Novel approaches for the treatment of frontotemporal dementia: is there hope for the future?

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Expert Review of Neurotherapeutics 2025-08-13

Frontotemporal dementia (FTD) refers to a group of neurodegenerative disorders characterized clinically by behavioral disturbances and pathologically by frontal and anterior temporal lobe neurodegeneration, resulting in brain atrophy. 5 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

History of hypertensive disorders of pregnancy and risk of Alzheimer’s disease and vascular dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Frontiers in Neuroendocrinology 2025-05-12

The incidence of dementia, and specifically, Alzheimer's disease, is higher in women than men, even in middle age, making it possible to rule out lifespan differences between men and women as a contributing factor. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multimodal magnetic resonance imaging analysis of early mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Alzheimer s Disease 2025-03-03

BackgroundEarly mild cognitive impairment (EMCI) represents a prodromal stage of dementia, and early detection is crucial for delaying dementia progression. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Revealing heterogeneity in mild cognitive impairment based on individualized structural covariance network

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s Research & Therapy 2025-05-15

In the ADNI dataset, MCI patients exhibited significant alterations in structural covariance edges, mainly involving the hippocampus, parahippocampal gyrus, and amygdala. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson’s disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Frontiers in Neurology 2025-08-29

Parkinson's disease (PD), as a common neurodegenerative disorder, its associated mild cognitive impairment (PD-mild cognitive impairment, PD-MCI) is a key prodromal stage in the progression to PD-dementia (PDD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Electroencephalography‐based signatures of cognitive resilience in individuals with stable mild cognitive impairment despite carrying a high‐risk for progression to dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia Translational Research & Clinical Interventions 2025-10-01

Compared with sMCI-resilient subjects, cMCI individuals exhibited increased frontal delta power, reduced posterior alpha power, and an elevated delta/alpha ratio in the right temporal region, consistent with cortical dysfunction. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Tau‐related reduction of glucose metabolism in mild cognitive impairment occurs independently of APOE ε4 genotype and is influenced by Aβ

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-02-01

We found cortical regions where a reduced glucose metabolism was maximally correlated with distributed patterns of tau, accounting for the effect of Aβ and APOE ε4 genotype. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Beyond the Clock: Exploring Multimodal Behavior Markers of Mild Cognitive Impairment in Older Adults during Clock Drawing Test

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Proceedings of the ACM on Interactive Mobile Wearable and Ubiquitous Technologies 2025-12-02

Early detection of Mild Cognitive Impairment (MCI) offers a critical window for intervention before progression to dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed